These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 30198339)

  • 1. Gene Therapy for Sickle Cell Disease: A Lentiviral Vector Comparison Study.
    Urbinati F; Campo Fernandez B; Masiuk KE; Poletti V; Hollis RP; Koziol C; Kaufman ML; Brown D; Mavilio F; Kohn DB
    Hum Gene Ther; 2018 Oct; 29(10):1153-1166. PubMed ID: 30198339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells.
    Urbinati F; Hargrove PW; Geiger S; Romero Z; Wherley J; Kaufman ML; Hollis RP; Chambers CB; Persons DA; Kohn DB; Wilber A
    Exp Hematol; 2015 May; 43(5):346-351. PubMed ID: 25681747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Titer and Gene Transfer by Lentiviral Vectors Using Novel, Small β-Globin Locus Control Region Elements.
    Morgan RA; Unti MJ; Aleshe B; Brown D; Osborne KS; Koziol C; Ayoub PG; Smith OB; O'Brien R; Tam C; Miyahira E; Ruiz M; Quintos JP; Senadheera S; Hollis RP; Kohn DB
    Mol Ther; 2020 Jan; 28(1):328-340. PubMed ID: 31628051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients.
    Breda L; Casu C; Gardenghi S; Bianchi N; Cartegni L; Narla M; Yazdanbakhsh K; Musso M; Manwani D; Little J; Gardner LB; Kleinert DA; Prus E; Fibach E; Grady RW; Giardina PJ; Gambari R; Rivella S
    PLoS One; 2012; 7(3):e32345. PubMed ID: 22479321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical studies for a phase 1 clinical trial of autologous hematopoietic stem cell gene therapy for sickle cell disease.
    Urbinati F; Wherley J; Geiger S; Fernandez BC; Kaufman ML; Cooper A; Romero Z; Marchioni F; Reeves L; Read E; Nowicki B; Grassman E; Viswanathan S; Wang X; Hollis RP; Kohn DB
    Cytotherapy; 2017 Sep; 19(9):1096-1112. PubMed ID: 28733131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders.
    Uchida N; Hsieh MM; Raines L; Haro-Mora JJ; Demirci S; Bonifacino AC; Krouse AE; Metzger ME; Donahue RE; Tisdale JF
    Nat Commun; 2019 Oct; 10(1):4479. PubMed ID: 31578323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin.
    Pestina TI; Hargrove PW; Jay D; Gray JT; Boyd KM; Persons DA
    Mol Ther; 2009 Feb; 17(2):245-52. PubMed ID: 19050697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enrichment of human hematopoietic stem/progenitor cells facilitates transduction for stem cell gene therapy.
    Baldwin K; Urbinati F; Romero Z; Campo-Fernandez B; Kaufman ML; Cooper AR; Masiuk K; Hollis RP; Kohn DB
    Stem Cells; 2015 May; 33(5):1532-42. PubMed ID: 25588820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-clinical Development of a Lentiviral Vector Expressing the Anti-sickling βAS3 Globin for Gene Therapy for Sickle Cell Disease.
    Poletti V; Urbinati F; Charrier S; Corre G; Hollis RP; Campo Fernandez B; Martin S; Rothe M; Schambach A; Kohn DB; Mavilio F
    Mol Ther Methods Clin Dev; 2018 Dec; 11():167-179. PubMed ID: 30533448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction of sickle cell disease in transgenic mouse models by gene therapy.
    Pawliuk R; Westerman KA; Fabry ME; Payen E; Tighe R; Bouhassira EE; Acharya SA; Ellis J; London IM; Eaves CJ; Humphries RK; Beuzard Y; Nagel RL; Leboulch P
    Science; 2001 Dec; 294(5550):2368-71. PubMed ID: 11743206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mass spectrometry assay for detection of endogenous and lentiviral engineered hemoglobin in cultured cells and sickle cell disease mice.
    Wang X; McKillop WM; Dlugi TA; Faber ML; Alvarez-Argote J; Chambers CB; Wilber A; Medin JA
    J Gene Med; 2024 Jan; 26(1):e3567. PubMed ID: 37455676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful correction of the human Cooley's anemia beta-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator.
    Malik P; Arumugam PI; Yee JK; Puthenveetil G
    Ann N Y Acad Sci; 2005; 1054():238-49. PubMed ID: 16339671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Mono- and Bi-Functional GLOBE-Based Vectors for Therapy of β-Thalassemia by
    Koniali L; Flouri C; Kostopoulou MI; Papaioannou NY; Papasavva PL; Naiisseh B; Stephanou C; Demetriadou A; Sitarou M; Christou S; Antoniou MN; Kleanthous M; Patsali P; Lederer CW
    Cells; 2023 Dec; 12(24):. PubMed ID: 38132168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease.
    Park SH; Lee CM; Dever DP; Davis TH; Camarena J; Srifa W; Zhang Y; Paikari A; Chang AK; Porteus MH; Sheehan VA; Bao G
    Nucleic Acids Res; 2019 Sep; 47(15):7955-7972. PubMed ID: 31147717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene replacement therapy for sickle cell disease and other blood disorders.
    Townes TM
    Hematology Am Soc Hematol Educ Program; 2008; ():193-6. PubMed ID: 19074080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene.
    Negre O; Eggimann AV; Beuzard Y; Ribeil JA; Bourget P; Borwornpinyo S; Hongeng S; Hacein-Bey S; Cavazzana M; Leboulch P; Payen E
    Hum Gene Ther; 2016 Feb; 27(2):148-65. PubMed ID: 26886832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates.
    Romero Z; Lomova A; Said S; Miggelbrink A; Kuo CY; Campo-Fernandez B; Hoban MD; Masiuk KE; Clark DN; Long J; Sanchez JM; Velez M; Miyahira E; Zhang R; Brown D; Wang X; Kurmangaliyev YZ; Hollis RP; Kohn DB
    Mol Ther; 2019 Aug; 27(8):1389-1406. PubMed ID: 31178391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correction of a mouse model of sickle cell disease: lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells.
    Levasseur DN; Ryan TM; Pawlik KM; Townes TM
    Blood; 2003 Dec; 102(13):4312-9. PubMed ID: 12933581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease.
    Ramadier S; Chalumeau A; Felix T; Othman N; Aknoun S; Casini A; Maule G; Masson C; De Cian A; Frati G; Brusson M; Concordet JP; Cavazzana M; Cereseto A; El Nemer W; Amendola M; Wattellier B; Meneghini V; Miccio A
    Mol Ther; 2022 Jan; 30(1):145-163. PubMed ID: 34418541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease.
    Germino-Watnick P; Hinds M; Le A; Chu R; Liu X; Uchida N
    Cells; 2022 Jun; 11(11):. PubMed ID: 35681538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.